Vésale Bioscience, a pioneer in the development of innovative, personalized and sustainable phage-based therapy solutions for tackling superbugs and antimicrobial resistance.
L’Écho
Vésale Bioscience named most innovative start-up in life sciences in Europe at tenth edition of BioFIT
La Libre
Vésale Bioscience enters into an innovative and ambitious collaboration with the Belgian Army
L’Écho
Vésale Bioscience raises a first tranche of €3 million: in preparation for its IPO, which has been brought forward to the end of 2022, Vésale Bioscience has raised a first tranche of funds from private investors.
This website uses cookies to improve your experience. We\'ll assume you\'re ok with this, but you can opt-out if you wish. Read MoreCookie SettingsAccept
Manage consent
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
